Received Feb 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | T9TL9 | — |
accidentally received the adult formulation of Havrix; accidentally received the adult formulation of Havrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult product administered to child in a 2-year-old male patient who received HAV (Havrix 1440 adult) (batch number T9TL9, expiry date 05-DEC-2025) for prophylaxis. On 03-FEB-2025, the patient received the 1st dose of Havrix 1440 adult. On 03-FEB-2025, an unknown time after receiving Havrix 1440 adult, the patient experienced adult product administered to child (Verbatim: accidentally received the adult formulation of Havrix) and accidental overdose (Verbatim: accidentally received the adult formulation of Havrix). The outcome of the adult product administered to child and accidental overdose were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-FEB-2025 Nurse reported that one of their patients who is 2 years old accidentally received the adult formulation of Havrix, which led to adult product administered to child and accidental overdose.